EGFR and neoplasm: Hence, as a non-invasive test, liquid biopsy has warranted wide attention in recent years with its unique advantage of simultaneously capturing multiple sites of tumor growth and testing EGFR mutation status, which could assist oncological clinicians in the timely adjustment of therapeutic strategies for NSCLC patients [9, 10].